Additional file 1 of Mechanisms of magnoliae cortex on treating sarcopenia explored by GEO gene sequencing data combined with network pharmacology and molecular docking

Additional file 1: Table S1. Differentially expressed genes related to sarcopenia in old people of GEO series.Table S2. Integrated data of sarcopenia related pathogenic genes. Table S3. Result of GO enrichment analysis for sarcopenia related pathogenic gene products. Table S4. Result of KEGG enrichment analysis for sarcopenia related pathogenic gene products. Table S5. Result of targets prediction of MC. Table S6. Composite targets of MC and sarcopenia. Table S7. Result of GO enrichment analysis for composite targets of MC and sarcopenia. Table S8. Result of KEGG enrichment analysis for composite targets of MC and sarcopenia. Table S9. Core proteins of MC-sarcopenia composite targets. Table S10. The affinity energy of Honokiol-AKT1. Table S11. The affinity energy of Magnolol-AKT1. Table S12. The affinity energy of Honokiol-EGFR. Table S13. The affinity energy of Magnolol-EGFR. Table S14. The affinity energy of Honokiol-INS. Table S15. The affinity energy of Magnolol-INS. Table S16. The affinity energy of Obovatol-PIK3CA. Figure S1. Sarcopenia related pathogenic gene products involve in EGFR tyrosine kinase inhibitor resistance (hsa01521). Figure S2. Sarcopenia related pathogenic gene products involve in endocrine resistance (hsa01522). Figure S3. Sarcopenia related pathogenic gene products involve in longevity regulating pathway (hsa04211). Figure S4. The GO and KEGG analysis of core sarcopenia-related pathogenic proteins. Figure S5. Core sarcopenia related pathogenic gene products involve in PI3K-Akt signaling pathway (hsa04151). Figure S6. Core sarcopenia related pathogenic gene products involve in longevity regulating pathway (hsa04213).

补充材料1：表S1。基因表达综合数据库（Gene Expression Omnibus, GEO）队列中与老年人肌肉减少症相关的差异表达基因。表S2：肌肉减少症相关致病基因整合数据集。表S3：肌肉减少症相关致病基因产物的基因本体（Gene Ontology, GO）富集分析结果。表S4：肌肉减少症相关致病基因产物的京都基因与基因组百科全书（Kyoto Encyclopedia of Genes and Genomes, KEGG）富集分析结果。表S5：MC的靶点预测结果。表S6：MC与肌肉减少症的复合靶点。表S7：MC与肌肉减少症复合靶点的GO富集分析结果。表S8：MC与肌肉减少症复合靶点的KEGG富集分析结果。表S9：MC-肌肉减少症复合靶点核心蛋白。表S10：和厚朴酚（Honokiol）与AKT1的结合亲和力能量。表S11：厚朴酚（Magnolol）与AKT1的结合亲和力能量。表S12：和厚朴酚与表皮生长因子受体（Epidermal Growth Factor Receptor, EGFR）的结合亲和力能量。表S13：厚朴酚与EGFR的结合亲和力能量。表S14：和厚朴酚与胰岛素（Insulin, INS）的结合亲和力能量。表S15：厚朴酚与INS的结合亲和力能量。表S16：Obovatol与磷脂酰肌醇-4,5-二磷酸3-激酶催化亚基α（PIK3CA）的结合亲和力能量。图S1：肌肉减少症相关致病基因产物参与表皮生长因子受体酪氨酸激酶抑制剂耐药通路（hsa01521）。图S2：肌肉减少症相关致病基因产物参与内分泌耐药通路（hsa01522）。图S3：肌肉减少症相关致病基因产物参与长寿调控通路（hsa04211）。图S4：肌肉减少症核心致病蛋白的GO与KEGG分析结果。图S5：肌肉减少症核心致病基因产物参与PI3K-Akt信号通路（hsa04151）。图S6：肌肉减少症核心致病基因产物参与长寿调控通路（hsa04213）。